Mainz Biomed N.V. (NASDAQ: MYNZ)

Mainz Biomed N.V., a public company based in the Netherlands, is a prominent player in the development and distribution of in-vitro diagnostic (IVD) tests for the early detection of cancer, with a particular focus on colorectal cancer (CRC) and pancreatic cancer. The company's flagship product, ColoAlert, is a CE-IVD certified CRC diagnostic test that utilizes molecular genetic stool tests to identify genetic anomalies and hidden blood in stool samples.

Mainz Biomed's primary business activities revolve around the creation and distribution of IVD tests for cancer detection. The company operates in the healthcare industry, specifically in the diagnostic sector. It conducts its operations primarily in Europe, particularly in Germany, and is currently expanding its reach to other regions.

The company generates revenue through the sale of its primary product, ColoAlert, and is in the process of developing another test, PancAlert, for the detection of pancreatic cancer. ColoAlert is a multitarget test that analyzes stool samples for genetic anomalies, including the quantification of human DNA, analysis of somatic point mutations in the KRAS (codon 12/13) and BRAF (codon 600) genes, and the presence of occult blood. The test has demonstrated high sensitivity and specificity in clinical studies, with a sensitivity of 85% and specificity of 92%.

In terms of competition, Mainz Biomed operates in a market with established players such as Exact Sciences Corporation, which also offers stool-based CRC screening tests. However, Mainz Biomed differentiates itself from competitors through its focus on molecular genetic stool tests and proprietary biomarkers, providing a competitive advantage.

Mainz Biomed's customers include healthcare professionals, laboratories, and patients. The company's products are used in hospitals, clinics, and private practices and are marketed and sold through a combination of direct sales, channel partnerships, and heightened product visibility.

In terms of brand names and trade names, Mainz Biomed's flagship product is ColoAlert. The company is also developing PancAlert for the detection of pancreatic cancer.